Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne virus causing serious infectious disease with a high case-fatality of up to 50% in severe cases. Currently, no effective drug has been approved for the treatment of SFTSV infection. Here, we performed a high-throughput screening of a natural extracts library for compounds with activities against SFTSV infection. Three hit compounds, notoginsenoside Ft1, punicalin, and toosendanin were identified for displaying high anti-SFTSV efficacy, in which, toosendanin showed the highest inhibition potency. Mechanistic investigation indicated that toosendanin inhibited SFTSV infection at the step of virus internalization. The anti-viral effect of toosendanin against SFTSV was further verified in mouse infection models, and the treatment with toosendanin significantly reduced viral load and histopathological changes in vivo . The antiviral activity of toosendanin was further expanded to another bunyavirus and the emerging SARS-CoV-2. This study revealed a broad anti-viral effect of toosendanin and indicated its potential to be developed as an anti-viral drug for clinical use.
【저자키워드】 SARS-CoV-2, SFTSV, bunyavirus, anti-viral drug screening, toosendanin, 【초록키워드】 Treatment, Efficacy, Infection, Infectious disease, antiviral activity, virus, Anti-viral, activity, Viral load, Fever, severe cases, anti-viral drug, compounds, Clinical use, Compound, syndrome, effective, highest, performed, significantly, indicated, inhibited, approved, reduced, changes in, histopathological, displaying, 【제목키워드】 Screening, Compound, library, molecule, Against,